Compare Stocks: CCCC, FBRX, KLRA, and ANAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$50.77 -5.8%	$55.57	$13.86 ▼ $72.36	$1.60B	0.71	489,961 shs	779,576 shs
CCCC C4 Therapeutics	$3.08 -6.9%	$3.71	$1.69 ▼ $5.17	$407.21M	2.94	1.73 million shs	4.59 million shs
FBRX Forte Biosciences	$76.99	$73.38	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
KLRA Kailera Therapeutics	$13.13 +2.7%	$16.62	$11.84 ▼ $28.23	$1.66B	N/A	922,459 shs	1.63 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-1.95%	-1.39%	-6.62%	-7.80%	+151.96%
CCCC C4 Therapeutics	+0.30%	-3.50%	-17.25%	-22.12%	+26.82%
FBRX Forte Biosciences	0.00%	0.00%	+0.09%	+315.26%	+420.91%
KLRA Kailera Therapeutics	+6.67%	-4.91%	-25.51%	-40.15%	+1,278,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$50.77 -5.8%	$55.57	$13.86 ▼ $72.36	$1.60B	0.71	489,961 shs	779,576 shs
CCCC C4 Therapeutics	$3.08 -6.9%	$3.71	$1.69 ▼ $5.17	$407.21M	2.94	1.73 million shs	4.59 million shs
FBRX Forte Biosciences	$76.99	$73.38	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A
KLRA Kailera Therapeutics	$13.13 +2.7%	$16.62	$11.84 ▼ $28.23	$1.66B	N/A	922,459 shs	1.63 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-1.95%	-1.39%	-6.62%	-7.80%	+151.96%
CCCC C4 Therapeutics	+0.30%	-3.50%	-17.25%	-22.12%	+26.82%
FBRX Forte Biosciences	0.00%	0.00%	+0.09%	+315.26%	+420.91%
KLRA Kailera Therapeutics	+6.67%	-4.91%	-25.51%	-40.15%	+1,278,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.69	Moderate Buy	$79.15	55.91% Upside
CCCC C4 Therapeutics	2.33	Hold	$7.00	127.27% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	225.59% Upside

Current Analyst Ratings Breakdown

Latest CCCC, FBRX, KLRA, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00
9/22/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/22/2026	ANAB AnaptysBio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	ANAB AnaptysBio	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$78.00
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.41	N/A	N/A	$1.34 per share	37.89
CCCC C4 Therapeutics	$35.95M	10.54	N/A	N/A	$2.65 per share	1.16
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	9.45	20.81	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CCCC, FBRX, KLRA, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
CCCC C4 Therapeutics	N/A	5.45	5.45
FBRX Forte Biosciences	N/A	10.01	10.01
KLRA Kailera Therapeutics	N/A	11.11	11.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
CCCC C4 Therapeutics	78.81%
FBRX Forte Biosciences	77.63%
KLRA Kailera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
CCCC C4 Therapeutics	5.60%
FBRX Forte Biosciences	4.40%
KLRA Kailera Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.61 million	20.28 million	Optionable
CCCC C4 Therapeutics	104	123.03 million	116.14 million	Optionable
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A

CCCC, FBRX, KLRA, and ANAB Headlines

Recent News About These Companies

Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week Low - Should You Sell?

September 22 at 4:40 AM | americanbankingnews.com

Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low - What's Next?

September 22 at 4:39 AM | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5% - Time to Sell?

September 21 at 1:39 PM | marketbeat.com

Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index

September 21 at 8:16 AM | marketscreener.comM

Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation

September 18, 2026 | seekingalpha.com

Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval

September 17, 2026 | seekingalpha.com

Kailera Therapeutics to Participate in Upcoming Investor Conferences

September 16, 2026 | quiverquant.comQ

Kailera Therapeutics to Participate in September Investor Conferences

September 16, 2026 | globenewswire.com

Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week Low - Time to Sell?

September 16, 2026 | marketbeat.com

Kailera Therapeutics Consensus Price Target Decreased by 10.48% to $47.94

September 16, 2026 | msn.com

Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”

September 14, 2026 | insidermonkey.com

Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Average Recommendation of "Moderate Buy" by Brokerages

September 14, 2026 | americanbankingnews.com

Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 14, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Reaches New 52-Week Low - Should You Sell?

September 12, 2026 | americanbankingnews.com

Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week Low - What's Next?

September 10, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7% - Should You Sell?

September 9, 2026 | marketbeat.com

Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA

September 7, 2026 | marketbeat.com

Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA

September 4, 2026 | marketbeat.com

2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP

September 3, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9% - Here's Why

September 1, 2026 | marketbeat.com

Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year Low - Should You Sell?

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, FBRX, KLRA, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$50.77 -3.15 (-5.84%)

Closing price 04:00 PM Eastern

Extended Trading

$50.82 +0.04 (+0.09%)

As of 07:30 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

C4 Therapeutics NASDAQ:CCCC

$3.08 -0.23 (-6.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.07 -0.01 (-0.26%)

As of 07:53 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Kailera Therapeutics NASDAQ:KLRA

$13.13 +0.34 (+2.66%)

As of 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, FBRX, KLRA, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, FBRX, KLRA, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, FBRX, KLRA, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, FBRX, KLRA, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

C4 Therapeutics NASDAQ:CCCC

Forte Biosciences NASDAQ:FBRX

Kailera Therapeutics NASDAQ:KLRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, FBRX, KLRA, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, FBRX, KLRA, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, FBRX, KLRA, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, FBRX, KLRA, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

C4 Therapeutics NASDAQ:CCCC

Forte Biosciences NASDAQ:FBRX

Kailera Therapeutics NASDAQ:KLRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools